Livingston Group Asset Management CO operating as Southport Capital Management Decreases Holdings in GlaxoSmithKline plc (GSK)

Livingston Group Asset Management CO operating as Southport Capital Management reduced its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 10.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,728 shares of the pharmaceutical company’s stock after selling 5,419 shares during the quarter. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in GlaxoSmithKline were worth $1,995,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Boenning & Scattergood Inc. lifted its position in shares of GlaxoSmithKline by 71.0% during the fourth quarter. Boenning & Scattergood Inc. now owns 55,061 shares of the pharmaceutical company’s stock worth $2,104,000 after purchasing an additional 22,867 shares in the last quarter. Norway Savings Bank lifted its position in shares of GlaxoSmithKline by 14.9% during the fourth quarter. Norway Savings Bank now owns 4,133 shares of the pharmaceutical company’s stock worth $158,000 after purchasing an additional 535 shares in the last quarter. Moody National Bank Trust Division lifted its position in shares of GlaxoSmithKline by 1.5% during the fourth quarter. Moody National Bank Trust Division now owns 34,108 shares of the pharmaceutical company’s stock worth $1,303,000 after purchasing an additional 508 shares in the last quarter. Cullinan Associates Inc. lifted its position in shares of GlaxoSmithKline by 27.2% during the fourth quarter. Cullinan Associates Inc. now owns 29,500 shares of the pharmaceutical company’s stock worth $1,127,000 after purchasing an additional 6,300 shares in the last quarter. Finally, Kahn Brothers Group Inc. DE lifted its position in shares of GlaxoSmithKline by 1.6% during the fourth quarter. Kahn Brothers Group Inc. DE now owns 1,260,940 shares of the pharmaceutical company’s stock worth $48,181,000 after purchasing an additional 19,424 shares in the last quarter. Institutional investors own 11.08% of the company’s stock.

GSK traded down $0.10 during trading on Wednesday, hitting $40.17. The company had a trading volume of 111,734 shares, compared to its average volume of 2,436,959. The stock has a market capitalization of $99.92 billion, a PE ratio of 12.69, a P/E/G ratio of 2.03 and a beta of 0.76. The company has a debt-to-equity ratio of 5.52, a current ratio of 0.75 and a quick ratio of 0.51. GlaxoSmithKline plc has a 1-year low of $36.41 and a 1-year high of $42.36.

GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.09. GlaxoSmithKline had a net margin of 11.45% and a return on equity of 160.39%. The firm had revenue of $10.55 billion during the quarter, compared to analyst estimates of $9.85 billion. On average, equities research analysts forecast that GlaxoSmithKline plc will post 2.91 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 22nd were paid a dividend of $0.597 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, February 21st. This represents a $2.39 annualized dividend and a yield of 5.95%. GlaxoSmithKline’s payout ratio is presently 75.32%.

A number of research analysts have recently commented on the stock. Shore Capital cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Zacks Investment Research raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Exane BNP Paribas cut shares of GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. BNP Paribas cut shares of GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. Finally, UBS Group cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $41.99.

ILLEGAL ACTIVITY WARNING: “Livingston Group Asset Management CO operating as Southport Capital Management Decreases Holdings in GlaxoSmithKline plc (GSK)” was reported by PressOracle and is the property of of PressOracle. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://pressoracle.com/news/2019/04/17/livingston-group-asset-management-co-operating-as-southport-capital-management-decreases-holdings-in-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.